Streptococcus pneumoniae Disease
Pediatric Infectious Disease Journal, January 1999;18:1-9
Acute Otitis Media - Management and Surveillance in an Era of Pneumococcal Resistance: A Report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group (DRSPTWG)
Scott F. Dowell, MD, MPH, Jay C. Butler, MD, G. Scott Giebink, MD, Michael R. Jacobs, MD, Daniel Jernigan, MD, Daniel M. Musher, MD, Alexander Rakowsky, MD, Benjamin Schwartz, MD, and the DRSPTWG*
Media / General Public Information
Healthcare Provider / Laboratory information
Centers for Disease Control and Prevention. Progress in Introduction of Pneumococcal Conjugate Vaccine -- Worldwide, 2000-2008. MMWR Morb Mortal Wkly Rep. 2008 Oct 23;57:1148-1151.
Moore MR, Robert E. Gertz J, Woodbury RL, Barkocy-Gallagher GA, Schaffner W, Lexau C, Gershman K, Reingold A, Farley M, Harrison LH, Hadler JL, Bennett NM, Thomas AR, McGee L, Pilishvili T, Brueggemann AB, Whitney CG, Jorgensen JH, Beall B. Population Snapshot of Emergent Streptococcus pneumoniae Serotype 19A in the United States, 2005. The Journal of Infectious Diseases. 2008;197:1016–27.
Park SY, Moore MR, Bruden DL, Hyde TB, Reasonover AL, Harker-Jones M, Rudolph KM, Hurlburt DA, Parks DJ, Parkinson AJ, Schuchat A, Hennessy TW. Impact of conjugate vaccine on transmission of antimicrobial-resistant Streptococcus pneumoniae among Alaskan children. Pediatr Infect Dis J. 2008 Apr;27:335-40.
Centers for Disease Control and Prevention. Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for use of 7-valent pneumococcal conjugate vaccine (PCV7) in children aged 24-59 months who are not completely vaccinated. MMWR Morb Mortal Wkly Rep. 2008 Apr 4;57:343-4.
Adamkiewicz TV, Silk BJ, Howgate J, Baughman W, Strayhorn G, Sullivan K, Farley MM. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life. Pediatrics. 2008 Mar;121:562-9.
Centers for Disease Control and Prevention. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005. MMWR Morb Mortal Wkly Rep. 2008 Feb 15;57:144-8.
World Health Organization. Meeting of the immunization Strategic Advisory Group of Experts, November 2007 – conclusions and recommendations. Weekly Epidemiological Record. 2008 4 January 2008;83:1-16.
Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Craig AS, Jackson D, Thomas A, Beall B, Lynfield R, Reingold A, Farley MM, Whitney CG. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis. 2007 Nov 1;196:1346-54.
Hsu K, Kellenberg J, Pelton S, Friedman D, Moore M, Jordan H. Emergence of Antimicrobial-Resistant Serotype 19A Streptococcus pneumoniae --- Massachusetts, 2001--2006. MMWR Morb Mortal Wkly Rep. 2007 Oct 19;56:1077-80.
Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet. 2007 Apr 7;369:1179-86.
Kyaw MH, Greene CM, Schaffner W, Ray SM, Shapiro M, Barrett NL, Gershman K, Craig AS, Roberson A, Zell ER, Schuchat A, Bennett NM, Whitney CG, Network atABCSPotEIP. Adults with invasive pneumococcal disease: missed opportunities for vaccination. American Journal of Preventive Medicine. 2006 October;31:286-92.
Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, Nyquist AC, Gershman KA, Vazquez M, Bennett NM, Reingold A, Thomas A, Glode MP, Zell ER, Jorgensen JH, Beall B, Schuchat A. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006 Oct 28;368:1495-502.
Greene CM, Kyaw MH, Ray SM, Schaffner W, Lynfield R, Barrett NL, Long C, Gershman K, Pilishvili T, Roberson A, Zell ER, Whitney CG, Bennett NM. Preventability of invasive pneumococcal disease and assessment of current polysaccharide vaccine recommendations for adults: United States, 2001-2003. Clin Infect Dis. 2006 Jul 15;43:141-50.
Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, Thomas AR, Harrison LH, Bennett NM, Farley MM, Facklam RR, Jorgensen JH, Besser J, Zell ER, Schuchat A, Whitney CG. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med. 2006 Apr 6;354:1455-63.
Flannery B, Heffernan RT, Harrison LH, Ray SM, Reingold AL, Hadler J, Schaffner W, Lynfield R, Thomas AR, Li J, Campsmith M, Whitney CG, Schuchat A. Changes in invasive pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization. Ann Intern Med. 2006 Jan 3;144:1-9.
Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, Harrison LH, Schaffner W, Reingold A, Bennett NM, Hadler J, Cieslak PR, Whitney CG. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA. 2005 Oct 26;294:2043-51.
Flannery B, Schrag S, Bennett NM, Lynfield R, Harrison LH, Reingold A, Cieslak PR, Hadler J, Farley MM, Facklam RR, Zell ER, Whitney CG. Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections. JAMA. 2004 May 12;291:2197-203.
Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2000: 49 (No. RR-9):1-35.
Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 1997; 46 (No. RR - 8): 1-25.